Pharmaceuticals News and Research

RSS

Mifepristone-eribulin combination clinically active in triple-negative breast cancer patients

Corcept Therapeutics Incorporated, a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced results of a multi-center Phase 1/2 dose-escalation study of mifepristone and chemotherapy drug eribulin (Halaven) that show it is well tolerated and clinically active in patients with triple-negative breast cancer.

15 May 2015

Chemical drug safely controls side effects associated with haploidentical stem cell transplantation

Researchers in the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist and Texas Children's Hospital have found that a single dose of an otherwise harmless drug can safely control the severe and often lethal side effects associated with haploidentical stem cell transplantation.

15 May 2015

Charity tackling antibiotic resistance welcomes latest O'Neill report

Antibiotic Research UK, the world’s first charity created to develop new antibiotics welcomes this latest O’Neill report and endorses whole heartedly its recommendations.

14 May 2015

APS announces recipients of prestigious achievement awards during annual scientific meeting

The American Pain Society (APS), www.americanpainsociety.org, today announced the recipients of its prestigious achievement awards during the organization's annual scientific meeting.

14 May 2015

Gadusol compound can provide a systemic sunscreen to humans

Researchers have discovered why many animal species can spend their whole lives outdoors with no apparent concern about high levels of solar exposure: they make their own sunscreen.

14 May 2015

ZenBio, Inc. introduces GroPro™ Cell Culture Growth Supplement formulated  to replace Bovine serum

ZenBio, Inc. industry leader in robust cell-based solutions, announced today the worldwide release of a new GroPro Cell Culture Growth Supplement...

14 May 2015

LABINDIA to promote Dotmatics’ scientific informatics solutions, services in India

Dotmatics, the leading provider of scientific informatics solutions and services for the pharma, biotech, chemicals, agrochemicals and academia announced today that it has appointed LABINDIA as a distributor in India.

14 May 2015

Miniature, fiber-optic microscope allows deep brain exploration

A team of neuroscientists and bioengineers at the University of Colorado Anschutz Medical Campus have created a miniature, fiber-optic microscope designed to peer deeply inside a living brain.

14 May 2015

CNIO researchers identify new strategy to combat cancer

Scientists from the Spanish National Cancer Research Centre have discovered a new strategy to fight cancer, which is very different from those described to date. Their work shows for the first time that telomeres -- the structures protecting the ends of the chromosomes -- may represent an effective anti-cancer target: by blocking the TRF1 gene, which is essential for the telomeres, they have shown dramatic improvements in mice with lung cancer.

14 May 2015

New approach to vaccine development is 97 per cent efficacious and could eliminate shingles

A new vaccine has proven almost completely effective in preventing shingles (disease medical name: herpes zoster), an extremely painful nerve infection which affects a third of Australians; most over the age of 50...

13 May 2015

Galmed reports net loss of $2.5 million for first quarter 2015

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases, today announced financial results for the three months ended March 31, 2015.

13 May 2015

Soligenix, Emergent BioSolutions sign development agreement

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has initiated a development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for the RiVax drug substance protein antigen.

13 May 2015

Research paves way for development of individualized immunotherapy for treating cancer

Mainz-based researchers have made significant advances with regard to the development of individualized immunotherapy strategies for treating cancer. They have managed to identify the relevant genetic changes or mutations associated with various types of cancer and have determined their individual blueprints.

13 May 2015

Lighthouse Instruments announces strategic business partnership with Robert Bosch

Lighthouse Instruments, LLC, a world leader in laser test and measurement systems for pharmaceutical process monitoring, today announced a strategic business partnership with Robert Bosch, GmbH to develop and distribute a new machine series for container closure integrity (CCI) testing using Lighthouse's laser headspace analysis (HSA) technology.

13 May 2015

DKSH supports Pfizer’s expansion to Laos

DKSH Business Unit Healthcare, the leading partner for healthcare companies seeking to grow their businesses in Asia, has signed an agreement to provide marketing, sales, logistics, distribution, credit management and -collection services to Pfizer in Laos.

12 May 2015

European Investment Bank supports Bavarian Nordic’s development of Ebola and cancer vaccines

The European Investment Bank (EIB), the world’s largest multilateral bank, today reaffirmed its firm commitment to respond to the Ebola pandemic. The Bank has provided a EUR 50 million loan to Bavarian Nordic, an international biopharmaceutical company, for accelerated development of an Ebola vaccine with long-term efficacy. The financing is also backing research into vaccines for treating other infectious diseases and multiple cancer indications.

12 May 2015

Inoviem Scientific receives €545,000 from French public investment bank bpifrance

Inoviem Scientific, a Contract Research Biotech (CRB) company today announces that it has received additional funding of €545,000 ($611,000) from French public investment bank bpifrance. The company leverages two proprietary technologies to offer pharmaceutical players increased speed and enhanced safety at all stages of drug development; from drug discovery (the identification of secondary targets and detection of potential adverse effects, etc.) through to clinical trials (with patient stratification and identification of biomarkers, etc.).

12 May 2015

Pharmaceuticals News and Research

Mifepristone-eribulin combination clinically active in triple-negative breast cancer patients

Chemical drug safely controls side effects associated with haploidentical stem cell transplantation

Charity tackling antibiotic resistance welcomes latest O'Neill report

APS announces recipients of prestigious achievement awards during annual scientific meeting

Gadusol compound can provide a systemic sunscreen to humans

ZenBio, Inc. introduces GroPro™ Cell Culture Growth Supplement formulated  to replace Bovine serum

LABINDIA to promote Dotmatics’ scientific informatics solutions, services in India

Miniature, fiber-optic microscope allows deep brain exploration

CNIO researchers identify new strategy to combat cancer

New approach to vaccine development is 97 per cent efficacious and could eliminate shingles

Galmed reports net loss of $2.5 million for first quarter 2015

Soligenix, Emergent BioSolutions sign development agreement

Research paves way for development of individualized immunotherapy for treating cancer

Lighthouse Instruments announces strategic business partnership with Robert Bosch

DKSH supports Pfizer’s expansion to Laos

European Investment Bank supports Bavarian Nordic’s development of Ebola and cancer vaccines

Inoviem Scientific receives €545,000 from French public investment bank bpifrance

PCMA releases new ad campaign to highlight lower-cost preferred pharmacy plans in Medicare

CPhI Istanbul 2015 opens as Turkey continues to dominate the MENA pharma region

China Pharma revenue decreases 20% to $5.7 million in Q1 2015

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring